Global Digital Therapeutics Market Projected to Surpass $12,695.60 Million, Growing at 20.0% CAGR in the 2021–2028 Timeframe [175-Pages] | Reasoning by Research Dive
January 02, 2023 09:01 ET | Research Dive
New York, USA, Jan. 02, 2023 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global digital therapeutics market. As per the report, the market is projected to hit $12,695.60...
Growth Plus Reports Logo.jpg
Central Nervous System Treatment Market Report (2022 to 2030) - Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Biogen Inc., and Novartis AG
December 15, 2022 06:44 ET | Growth Plus Reports
Pune, Dec. 15, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global central nervous system treatment market is expected to clock US$ 191.01 billion by...
Multiple Sclerosis Therapeutics Market Size Worth $39.22 Bn by 2027 – The Insight Partners
November 09, 2022 09:12 ET | The Insight Partners
New York, Nov. 09, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners new research study titled "Multiple Sclerosis Therapeutics Market Size, Share, Growth and Forecast to 2027 – COVID-19...
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes
September 22, 2022 07:46 ET | SciSparc Ltd
TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
AMR Logo.png
Global Digital Therapeutics Market is Expected to Reach $22.60 Billion, at of 19.4% by 2031: Allied Market Research
September 01, 2022 09:00 ET | Allied Market Research
Portland, OR, Sept. 01, 2022 (GLOBE NEWSWIRE) -- The global Digital Therapeutics Market generated $3.84 billion in 2021, and is projected to reach $22.60 billion by 2031, registering a CAGR of 19.4%...
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
August 24, 2022 07:30 ET | SciSparc Ltd
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a...
Scisparc Announces the Full Exercise of Pre-Funded Warrants
August 19, 2022 06:45 ET | SciSparc Ltd
The pre-funded warrants were issued as part of the $10 million private placement from June 2022 TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
August 01, 2022 09:30 ET | SciSparc Ltd
The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE)...
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
July 08, 2022 08:30 ET | SciSparc Ltd
TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility
July 07, 2022 08:30 ET | SciSparc Ltd
The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a...